Inspire Medical Systems reported a modest 1.6% revenue growth in Q1 and lowered its 2026 guidance by up to 10%, citing increased competition from GLP-1 drugs and rival devices, reimbursement challenges, and coding issues with its new Inspire 5 system. The company is also facing operational headwinds as it contracts territories and shifts focus to supporting existing accounts rather than expanding aggressively. Despite a 20% drop in its stock price, the current valuation still assumes optimistic growth and margin improvements that are not supported by recent results. The analyst maintains a Sell rating on the stock due to these challenges and uncertainties.
Investec Bank plc, acting as a joint broker for Gamma Communications Plc, disclosed a public dealing on July 27, 2026, involving the purchase and sale of 96,419 ordinary shares of Gamma Communications. The transactions were executed at prices ranging...
Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, disclosed public dealings under the Takeover Code on July 27, 2026. The bank purchased 8,073 ordinary shares at prices between 1220 and 1230 pence and sold 6,000 shares at price...
Alstom and its partners have finalized financing for the Haifa-Nazareth light rail project in Israel, valued at around €2 billion, with Alstom's share at approximately €750 million. The 41-kilometer line will connect Haifa, Nazareth, and nearby commu...
Alstom and its consortium partners have reached financial close for the Haifa-Nazareth light rail project in Israel, a major step enabling full-scale execution. The €2 billion project will build a 41-kilometer light rail line connecting Haifa, Nazare...
The global strategy consulting market, valued at $81.51 billion in 2025, is projected to grow to $194.56 billion by 2035 with a CAGR of 9.09%. Growth is fueled by increasing demand for digital transformation, AI-powered advisory services, ESG consult...
